Phase II trial of rituximab-ABVD [doxorubicin + bleomycin + vinblastine + dacarbazine] for classical Hodgkin's disease
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2013 Planned end date changed from 1 May 2009 to 1 May 2014 as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.